Tumor Lysis Syndrome | Hematology | JAMA Oncology | JAMA Network

https://jamanetwork.com/journals/jamaoncology/fullarticle/2680750

JAMA Oncology Patient Page
May 10, 2018
Tumor Lysis Syndrome
Arjun Gupta, MD; Joseph A. Moore, MD
Article Information
JAMA Oncol. Published online May 10, 2018. doi:10.1001/jamaoncol.2018.0613
Image description not available.
Tumor lysis syndrome (TLS) is a condition that occurs when a large number of cancer cells die within a short period, releasing their contents in to the blood.

How Does TLS Affect the Body?
When cancer cells break down quickly in the body, levels of uric acid, potassium, and phosphorus rise faster than the kidneys can remove them. This causes TLS. Excess phosphorus can “sop up” calcium, leading to low levels of calcium in the blood. Changes in blood levels of uric acid, potassium, phosphorus, and calcium can affect the functioning of several organs, especially the kidneys, and also the heart, brain, muscles, and gastrointestinal tract.

Who Develops TLS?
Not all cancer patients are at equal risk of developing TLS. Patients with a large “tumor burden” of cancer cells and/or tumors that typically have rapidly dividing cells, such as acute leukemia or high-grade lymphoma, as well as tumors that are highly responsive to therapy, are at greatest risk of developing TLS. TLS can occur spontaneously (before cancer treatment) but is more common within a week of starting treatment. TLS is not limited to patients receiving traditional chemotherapy; it can also occur in patients receiving steroids, hormonal therapy, targeted therapy, or radiation therapy. Patients who are dehydrated and those with existing kidney dysfunction are at higher risk of developing TLS.

What Are the Symptoms of TLS, and How Is It Diagnosed?
Symptoms are generally nonspecific and can include:

Nausea with or without vomiting

Lack of appetite and fatigue

Dark urine, reduced urine output, or flank pain

Numbness, seizures, or hallucinations

Muscle cramps and spasms

Heart palpitations

Kidney failure and death can occur, especially if TLS is left untreated.

TLS is diagnosed based on blood tests, along with signs and symptoms. Its onset may be subtle, with only a few abnormal laboratory values, but it can also present with frank kidney and organ failure.

Can TLS Be Prevented?
Certain measures can reduce the chances of developing TLS. Your clinician will consider results of blood tests and characteristics of the cancer to determine your risk of developing TLS and which preventive measure(s) to use. Intravenous fluids can help the kidneys to flush out toxins in the urine. Medications such as allopurinol and rasburicase reduce uric acid levels in the blood and may be prescribed.

How Is TLS Treated?
Even with preventive measures, TLS can still develop. Patients at high risk of TLS undergo bloodwork and clinical monitoring before and during therapy to ensure early diagnosis if it develops. Treatment is similar to the preventive measures, including intravenous fluids, allopurinol, and especially rasburicase. Patients may require admission to the intensive care unit. Bloodwork is repeated frequently to assess electrolyte levels and kidney damage, and the heart rhythm and urine output are closely monitored. Careful correction of electrolyte imbalances is required. Some patients with severe kidney injury may require temporary hemodialysis.

For More Information
Canadian Cancer Society: Tumor Lysis Syndrome
http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/managing-side-effects/tumour-lysis-syndrome/?region=on

Section Editor: Howard (Jack) West, MD.
The JAMA Oncology Patient Page is a public service of JAMA Oncology. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA Oncology suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call (312) 464-0776.
Back to top
Article Information
Published Online: May 10, 2018. doi:10.1001/jamaoncol.2018.0613

Conflict of Interest Disclosures: None reported.

See More About
Hematology Oncology Patient Information Hematologic Cancer Lymphomas Leukemias JAMA Oncology Patient

Advertisements

Leave a Reply: (What... You're shy?)

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s